

**VANCOUVER GENERAL HOSPITAL
CSU PHARMACEUTICAL SCIENCES
SPECIAL ACCESS DRUG DATA SHEET**

DRUG NAME

quinupristin + dalfopristin

ALTERNATE NAME

Synercid®

MANUFACTURER

Pfizer

STRENGTH

500mg vial (150mg quinupristin + 350mg dalfopristin)

DOSAGE FORM

injectable

INDICATIONS

- Used primarily for patients with Gram-positive infections, including Methicillin-Resistant *Staphylococcus aureus* (MRSA) and Vancomycin Resistant *Enterococcus faecium* (VRE), where alternative treatment options have failed or are contraindicated.
-

DOSAGE

- 7.5 mg (of combination)/kg IV Q8H or Q12H
-

ADMINISTRATION

- Infuse over 60 minutes
 - Following completion of a peripheral line infusion, flush line with D5W to minimize venous irritation
 - DO NOT flush with NS solutions or solutions containing heparin
 - Volume of infusion bag may be increased to 500-750mL to reduce venous irritation
-

PREPARATION

- Reconstitute each vial with 5mL of SWFI or D5W (concentration: 100mg/mL)
 - GENTLY swirl the vial to dissolve. DO NOT shake.
 - Allow the solution to sit until all the foam has disappeared (solution should be clear)
 - Reconstituted solution is stable for 30 minutes. Discard unused portions
 - Compatible in D5W ONLY
 - For central lines: minimum volume 100mL
 - For peripheral IV: minimum volume 250mL
 - Prepared IV bag is stable for 5 hours at room temperature and for 54 hours in the fridge
-

KNOWN SIDE EFFECTS*

- Venous irritation, arthralgia, myalgia, hyperbilirubinemia, and diarrhea
-

SPECIAL PRECAUTIONS

- Incompatible with NS and heparin
 - Do not mix with other medications in the same infusion bag
 - Quinupristin + dalfopristin (Synercid®) is a significant cytochrome P450 3A4 inhibitor. Co-administration with cytochrome P450 3A4 substrate drugs that have a narrow therapeutic window requires caution and close monitoring, when possible. (E.g. cyclosporine, midazolam, nifedipine, terfenadine)
 - Concomitant medications metabolized by cytochrome P450 3A4 enzyme system that prolongs QTc interval should be avoided
 - Please refer to product monograph for more detailed information
 - Quinupristin + dalfopristin (Synercid®) is not available on the Canadian Market. Approval from the Special Access Programme is required prior to use
-

***REPORT ANY ADVERSE DRUG REACTIONS TO CSU PHARMACEUTICAL SCIENCES**

REV 20FEB2017 (TL/JY)